Duke University cancer researcher Prof Donald McDonnell on BTYSTE and how learning the scientific process at an early age is ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...

The server maker's shares have climbed more than 30% over the past four days, powered higher by two bits of good news.